M. Rothermundt

V. Arolt, B. Svensson, D. Kögel, 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Identification of a biological signature for schizophrenia in serum

Michael D. Spain, R. Yolken, S. Baron-Cohen, 2012, Molecular Psychiatry.

Reduced implicit and explicit sequence learning in first-episode schizophrenia

T. Suslow, V. Arolt, P. Ohrmann, 2008, Neuropsychologia.

Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia

Michael D. Spain, A. Barnes, P. Guest, 2011, Psychoneuroendocrinology.

Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY‐cleaving peptidases and potential drug interactions in CNS and Periphery

B. Leavitt, M. Rothermundt, J. Rahfeld, 2015, Journal of neurochemistry.

Neuropeptide S Receptor (NPSR) Gene - Converging Evidence for a Role in Panic Disorder

A. Gloster, G. Alpers, W. Maier, 2020 .

Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins.

Jayne E. Telford, P. Guest, S. Bahn, 2012, Journal of proteome research.

Inflammatory markers in major depression and melancholia.

A. Kersting, V. Arolt, M. Rothermundt, 2001, Journal of affective disorders.

S100B and response to treatment in major depression: a pilot study

M. Wiesmann, V. Arolt, U. Missler, 2003, European Neuropsychopharmacology.

Autocrine S100B effects on astrocytes are mediated via RAGE

V. Arolt, M. Rothermundt, C. Schettler, 2007, Journal of Neuroimmunology.

S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury

V. Arolt, D. Kögel, M. Rothermundt, 2004, Neuroscience.

S-100B is increased in melancholic but not in non-melancholic major depression.

M. Wiesmann, V. Arolt, U. Missler, 2001, Journal of affective disorders.

Different immune patterns in melancholic and non-melancholic major depression

V. Arolt, M. Rothermundt, H. Kirchner, 2001, European Archives of Psychiatry and Clinical Neuroscience.

Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.

T. Suslow, V. Arolt, N. Michael, 2003, Journal of psychiatric research.

Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation

T. Hoffmann, M. Rothermundt, J. Rahfeld, 2016, Neuropeptides.

Immunological research in clinical psychiatry: report on the consensus debate during the 7th expert meeting on psychiatry and immunology

V. Arolt, B. Leonard, M. Rothermundt, 2002, Molecular Psychiatry.

Immunological Dysfunction in Schizophrenia: A Systematic Approach

V. Arolt, M. Rothermundt, H. Kirchner, 1998, Neuropsychobiology.

Cytokines in schizophrenia. Results from a longitudinal study

V. Arolt, M. Rothermundt, H. Kirchner, 1997 .

Therapeutic strategies for catatonia in paraneoplastic encephalitis

V. Arolt, M. Zavorotnyy, M. Weckesser, 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy

N. Michael, P. Guest, S. Bahn, 2011, Proteomics. Clinical applications.

311547-Journal vol 5/1 Jan 04

V. Arolt, A. Broocks, M. Rothermundt, 2005 .

Search for atypical lymphocytes in schizophrenia

V. Arolt, A. Broocks, M. Rothermundt, 2004, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

S100B in brain damage and neurodegeneration

V. Arolt, M. Rothermundt, J. Prehn, 2003, Microscopy research and technique.

Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia

Michael D. Spain, R. Yolken, B. Bogerts, 2010, Biomarker insights.

Depression associated with antiretroviral drug therapy in HIV: case report and overview

S. Evers, M. Rothermundt, D. Reichelt, 2012, International journal of STD & AIDS.

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

Michael F. Green, Max W. Y. Lam, Catherine A. Sugar, 2022, Nature.

Neuropeptide S receptor gene — converging evidence for a role in panic disorder

A. Gloster, G. Alpers, W. Maier, 2011, Molecular Psychiatry.

Chromosome 4q31‐34 panic disorder risk locus: Association of neuropeptide Y Y5 receptor variants

W. Maier, V. Arolt, K. Domschke, 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Clinical use of phosphorylated proteins in blood serum analysed by immobilised metal ion affinity chromatography and mass spectrometry.

P. Guest, S. Bahn, F. Leweke, 2012, Journal of proteomics.

Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder

M. Gill, M. Hill, D. Morris, 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals

C. Freitag, K. Domschke, J. Deckert, 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes

P. Deyn, S. Engelborghs, S. Claes, 2011, Psychiatry Research.

Clinical psychoneuroimmunology.

M. Irwin, M. Rothermundt, 2012, Handbook of clinical neurology.

S100B in schizophrenic psychosis.

V. Arolt, M. Rothermundt, G. Ponath, 2004, International review of neurobiology.

Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study

C. Meisinger, B. Baune, K. Berger, 2011, AGE.

Adenosine A 2 A receptor gene ( ADORA 2 A ) variants may increase autistic symptoms and anxiety in autism spectrum disorder

C. Freitag, A. Gontard, J. Deckert, 2018 .

Adenosine A2A receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder

Christa Hohoff, Jürgen Deckert, Christine M. Freitag, 2009, European Child & Adolescent Psychiatry.

CHAPTER 27 – Schizophrenia and Immunity

V. Arolt, M. Rothermundt, 2007 .

Review of Immunological and Immunopathological Findings in Schizophrenia

T. Bayer, V. Arolt, M. Rothermundt, 2001, Brain, Behavior, and Immunity.

Production of interferon-gamma in families with multiple occurrence of schizophrenia

V. Arolt, M. Rothermundt, A. Nolte, 1997, Psychiatry Research.

Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls.

P. Guest, S. Bahn, F. Leweke, 2012, Journal of proteomics.

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients

V. Arolt, M. Rothermundt, H. Kirchner, 2005, European Archives of Psychiatry and Clinical Neuroscience.

Association Between Cytokines and Cerebral MRI Changes in the Aging Brain

Bernhard T. Baune, Andreas Roesler, Klaus Berger, 2009, Journal of geriatric psychiatry and neurology.

100 B in schizophrenia : an update

M. Rothermundt, S. Jörgens, J. Ahn, 2010 .

Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia

T. Suslow, V. Arolt, P. Ohrmann, 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Serum levels of S100B are decreased in chronic starvation and normalize with weight gain

B. Herpertz-Dahlmann, J. Hebebrand, M. Rothermundt, 2008, Journal of Neural Transmission.

Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol

T. Suslow, V. Arolt, W. Heindel, 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF

P. Falkai, W. Maier, T. Suslow, 2004, Molecular Psychiatry.

S100B Serum Levels and Long-Term Improvement of Negative Symptoms in Patients with Schizophrenia

V. Arolt, M. Rothermundt, G. Ponath, 2004, Neuropsychopharmacology.

Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology

M. Wiesmann, V. Arolt, U. Missler, 2001, Molecular Psychiatry.

Production of cytokines in acute schizophrenic psychosis

V. Arolt, M. Rothermundt, H. Kirchner, 1996, Biological Psychiatry.

S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence.

V. Arolt, Weiqi Zhang, M. Rothermundt, 2013, Journal of psychiatric research.

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

V. Arolt, M. Rothermundt, H. Kirchner, 2000, Molecular Psychiatry.

Prenatal immune activation in mice blocks the effects of environmental enrichment on exploratory behavior and microglia density

V. Arolt, Weiqi Zhang, M. Rothermundt, 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Increased serum neopterin levels in acutely ill and recovered schizophrenic patients

V. Arolt, M. Rothermundt, H. Kirchner, 1998, Schizophrenia Research.

S100B in schizophrenia: an update.

M. Rothermundt, S. Jörgens, J. Ahn, 2009, General physiology and biophysics.

Target evaluation processing and serum levels of nerve tissue protein S100B in patients with remitted major depression

M. Wiesmann, V. Arolt, D. Dietrich, 2004, Neuroscience Letters.

Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates

V. Arolt, U. Dannlowski, B. Baune, 2008, Human psychopharmacology.

Cytokine production in depressed patients.

M. Rothermundt, L. Rink, A. Seidel, 1999, Advances in experimental medicine and biology.

Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy

Volker Arolt, Patricia Ohrmann, Thomas Suslow, 2008, Schizophrenia Research.

Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways.

J. M. Ramsey, B. Bogerts, P. Guest, 2014, Schizophrenia bulletin.

Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia

H. Sauer, S. Smesny, Christian Gaser, 2016, Front. Cell. Neurosci..

S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression

V. Arolt, J. Alferink, V. Bergink, 2015, The international journal of neuropsychopharmacology.

Association between genetic variants of IL-1beta, IL-6 and TNF-alpha cytokines and cognitive performance in the elderly general population of the MEMO-study.

Olaf Riess, Klaus Berger, Bernhard T Baune, 2008, Psychoneuroendocrinology.

Sexual Impairment in Psychiatric Inpatients: Focus on Depression

A. Erfurth, M. Rothermundt, S. Bender, 2007, Pharmacopsychiatry.

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

R. Yolken, B. Crespo-Facorro, M. Krebs, 2015, Translational Psychiatry.

Association between IL-8 cytokine and cognitive performance in an elderly general population—The MEMO-Study

V. Arolt, B. Baune, K. Berger, 2008, Neurobiology of Aging.

Psychoimmunological alterations in schizophrenia: how do confounding variables influence the findings?

V. Arolt, M. Rothermundt, H. Kirchner, 1999 .

Molecular serum signature of treatment resistant depression

V. Arolt, J. Cooper, S. Bahn, 2018 .

Blood-based immune-endocrine biomarkers of treatment response in 2 depression 3 4 5 6 7 Running

B. Penninx, J. Cooper, H. Drexhage, 2017 .

Cognitive Impairment and in Vivo Metabolites in First-episode Neuroleptic-naive and Chronic Medicated Schizophrenic Patients: a Proton Magnetic Resonance Spectroscopy Study

A. Kersting, T. Suslow, V. Arolt, 2006 .

The Influence of Typical and Atypical Neuroleptic Drugs in the Production of Interleukin-2 and Interferon-Gamma in vitro

V. Arolt, M. Rothermundt, H. Kirchner, 2003, Neuropsychobiology.

Neural correlates of set-shifting: decomposing executive functions in schizophrenia.

T. Suslow, V. Arolt, P. Ohrmann, 2010, Journal of psychiatry & neuroscience : JPN.

Association between genetic variants of IL-1β, IL-6 and TNF-α cytokines and cognitive performance in the elderly general population of the MEMO-study

Bernhard T. Baune, Olaf Riess, Klaus Berger, 2008, Psychoneuroendocrinology.

Effects of amantadine treatment on in vitro production of interleukin-2 in de-novo patients with idiopathic Parkinson's disease

P. Vieregge, M. Rothermundt, J. Hagenah, 1999, Journal of Neuroimmunology.

Towards a blood-based diagnostic panel for bipolar disorder

R. Yolken, B. Penninx, B. Crespo-Facorro, 2016, Brain, Behavior, and Immunity.

Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity.

V. Arolt, M. Rothermundt, M. Hettich, 2005, Journal of affective disorders.

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

M. Wiesmann, V. Arolt, D. Dietrich, 2009, Neuropsychobiology.

The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment

Volker Arolt, Stefan Evers, Guenter Hetzel, 2005, Psychopharmacology.

Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality.

C. Freitag, W. Maier, F. Holsboer, 2010, Journal of psychiatric research.

Naturalistic Pharmacotherapy of Acute Episodes of Schizophrenic Disorders in Comparison to Treatment Guidelines

V. Arolt, D. Dietrich, H. Emrich, 2012, Pharmacopsychiatry.

Molecular serum signature of treatment resistant depression

V. Arolt, J. Cooper, S. Bahn, 2016, Psychopharmacology.

Normal Cerebellar Development in S100B-Deficient Mice

M. Rothermundt, Björn Bluhm, B. Laffer, 2015, The Cerebellum.

Distinct regulation of brain-derived neurotrophic factor and noradrenaline in S100B knockout mice

R. Hellweg, M. Rothermundt, O. Schulte-Herbrüggen, 2008, Neuroscience Letters.

Immunocompetent Cells in Melancholic and Non-Melancholic Major Depression

V. Arolt, M. Rothermundt, H. Kirchner, 2001 .

Molecular Sex Differences in Human Serum

J. M. Ramsey, S. Baron-Cohen, B. Bogerts, 2012, PloS one.

Basal Prolactin Values Correlate with Response to Reboxetine Treatment in Major Depression, but Not with Response to Citalopram

V. Arolt, N. Michael, A. Erfurth, 2005, Neuropsychobiology.

Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients

P. Guest, S. Bahn, J. Steiner, 2016, Brain, Behavior, and Immunity.

Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy

T. Suslow, V. Arolt, P. Ohrmann, 2008, Schizophrenia Research.

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.

A. Kersting, T. Suslow, V. Arolt, 2007, Journal of psychiatric research.

S100B Serum Levels and Word Memory Processing in Remitted Major Depression as Reflected by Brain Potentials

M. Wiesmann, V. Arolt, D. Dietrich, 2009, Neuropsychobiology.

Clinical psychoneuroimmunology.

M. Irwin, M. Rothermundt, 2012, Handbook of clinical neurology.